Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients

FOLFIRINOX is superior to gemcitabine in patients with pancreatic cancer, but this regimen is associated with toxicity and biomarkers for response are warranted. MicroRNAs can mediate drug resistance and could provide predictive information. Altered expressions of several microRNAs including miR-21-...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Konstantin Schlick, Florian Hohla, Frank Hamacher, Hubert Hackl, Clemens Hufnagl, Steiner Markus, Teresa Magnes, Simon Peter Gampenrieder, Thomas Melchardt, Stefan Stättner, Cornelia Hauser-Kronberger, Richard Greil, Gabriel Rinnerthaler
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2021-02-01
coleção:	Future Science OA
Assuntos:	FOLFIRINOX gemcitabine miRNA pancreatic cancer
Acesso em linha:	https://www.future-science.com/doi/10.2144/fsoa-2020-0128
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!